Ardelyx, Inc. (FRA:41X)

Market Cap	1.19B -5.6%
Revenue (ttm)	346.91M +22.1%
Net Income	-52.46M
EPS	-0.22
Shares Out	n/a
PE Ratio	n/a
Forward PE	142.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	800
Average Volume	190
Open	5.31
Previous Close	5.76
Day's Range	5.06 - 5.48
52-Week Range	2.89 - 6.75
Beta	n/a
RSI	32.19
Earnings Date	Feb 19, 2026

About Ardelyx

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. The company was incorporated in 2007 an...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 395
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 41X

Financial Performance

In 2025, Ardelyx's revenue was $407.32 million, an increase of 22.09% compared to the previous year's $333.62 million. Losses were -$61.60 million, 57.4% more than in 2024.

Financial numbers in USD